schliessen

Filtern

 

Bibliotheken

New advances that enable identification of glioblastoma recurrence

Postoperative adjuvant radiation therapy and temozolomide chemotherapy have become the standard care for newly diagnosed malignant gliomas. The efficacy of these therapies has led to an increase in pseudoprogression and radiation necrosis, both of which are treatment-related effects whose appearance... Full description

Journal Title: Nature reviews. Clinical oncology 2009-11, Vol.6 (11), p.648-657
Main Author: Aghi, Manish K
Other Authors: Yang, Isaac
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Nature Publishing Group
ID: ISSN: 1759-4774
Link: https://www.ncbi.nlm.nih.gov/pubmed/19806145
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_1029874794
title: New advances that enable identification of glioblastoma recurrence
format: Article
creator:
  • Aghi, Manish K
  • Yang, Isaac
subjects:
  • Antineoplastic Agents, Alkylating - therapeutic use
  • Care and treatment
  • Dacarbazine - analogs & derivatives
  • Dacarbazine - therapeutic use
  • Development and progression
  • Diagnosis
  • Diffusion Magnetic Resonance Imaging - methods
  • Glioblastoma - drug therapy
  • Glioblastoma - pathology
  • Glioblastoma - radiotherapy
  • Glioblastoma multiforme
  • Health aspects
  • Humans
  • Magnetic Resonance Imaging - methods
  • Magnetic Resonance Spectroscopy - methods
  • Neoplasm Recurrence, Local - diagnosis
  • Neoplasm Recurrence, Local - pathology
  • Nuclear magnetic resonance spectroscopy
  • PET imaging
  • Positron-Emission Tomography - methods
  • Radiation Injuries - diagnosis
  • Radiotherapy
  • Randomized Controlled Trials as Topic
  • Usage
ispartof: Nature reviews. Clinical oncology, 2009-11, Vol.6 (11), p.648-657
description: Postoperative adjuvant radiation therapy and temozolomide chemotherapy have become the standard care for newly diagnosed malignant gliomas. The efficacy of these therapies has led to an increase in pseudoprogression and radiation necrosis, both of which are treatment-related effects whose appearance on standard MRI with gadolinium-based contrast agents resembles that of tumor progression or recurrence. Accurate diagnosis of these post-treatment lesions as either tumor recurrence or treatment effects (pseudoprogression or radiation necrosis) is important to determine the patient's prognosis. Modern advancements with magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and PET scans have shown promise for distinguishing tumor recurrence from treatment effects. Advances in radiographic techniques will become critically important with the emergence of new antiangiogenic therapies. Consequently, MRS, DWI, and PET need to be incorporated into routine post-treatment investigations to improve the specificity and sensitivity of distinguishing tumor recurrence from treatment effects. Further research will also be needed to develop improved algorithms that use these modalities, and to develop new modalities with even greater accuracy than those currently available.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1759-4774
fulltext: fulltext
issn:
  • 1759-4774
  • 1759-4782
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5443442
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_journals_1029874794
sourceformatXML
sourcesystemPC
galeidA211366335
sourcerecordidA211366335
originalsourceidFETCH-LOGICAL-c451t-a19008db45440ed2efbaa7aabe1d4dac54a1614ce22e4056f5f7da5be02a0b113
addsrcrecordideNp9kU1vVCEYhYnR2Fr9Ay7MTUyMm5kCF-7HsjZ-JY3d6Jq8F146NFyowLXpv5dxJlNrGsMCQp5z3gOHkNeMrhlth9OQtHchBr3mlI5rJukTcsx6Oa5EP_Cnh3MvjsiLnK8p7TrRt8_JERsH2jEhj8mHb3jbgPkFQWNuygZKgwEmj40zGIqzTkNxMTTRNlfexclDLnGGJqFeUsIqe0meWfAZX-33E_Lj08fv519WF5efv56fXay0kKysgI2UDmYSUgiKhqOdAHqACZkRBrQUwGomjZyjoLKz0vYG5ISUA50Ya0_I253vTYo_F8xFXcclhTpSMcrHoRf9KO6pK_CoXLCxJNCzy1qd8erSdW0rK7V-hKrL4Ox0DGhdvX8gePeXYIPgyyZHv2z_Jj8E-Q7UKeac0Kqb5GZIdzWk2tamDrWpbW2q1lZFb_ZPW6YZzb1k31MFhn9ctSt_iqm5nf-_9_udNEBZEh68H0F_Azlwtag
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1029874794
display
typearticle
titleNew advances that enable identification of glioblastoma recurrence
sourceAlma/SFX Local Collection
creatorAghi, Manish K ; Yang, Isaac
creatorcontribAghi, Manish K ; Yang, Isaac
descriptionPostoperative adjuvant radiation therapy and temozolomide chemotherapy have become the standard care for newly diagnosed malignant gliomas. The efficacy of these therapies has led to an increase in pseudoprogression and radiation necrosis, both of which are treatment-related effects whose appearance on standard MRI with gadolinium-based contrast agents resembles that of tumor progression or recurrence. Accurate diagnosis of these post-treatment lesions as either tumor recurrence or treatment effects (pseudoprogression or radiation necrosis) is important to determine the patient's prognosis. Modern advancements with magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and PET scans have shown promise for distinguishing tumor recurrence from treatment effects. Advances in radiographic techniques will become critically important with the emergence of new antiangiogenic therapies. Consequently, MRS, DWI, and PET need to be incorporated into routine post-treatment investigations to improve the specificity and sensitivity of distinguishing tumor recurrence from treatment effects. Further research will also be needed to develop improved algorithms that use these modalities, and to develop new modalities with even greater accuracy than those currently available.
identifier
0ISSN: 1759-4774
1EISSN: 1759-4782
2DOI: 10.1038/nrclinonc.2009.150
3PMID: 19806145
4CODEN: AJHYE6
languageeng
publisherEngland: Nature Publishing Group
subjectAntineoplastic Agents, Alkylating - therapeutic use ; Care and treatment ; Dacarbazine - analogs & derivatives ; Dacarbazine - therapeutic use ; Development and progression ; Diagnosis ; Diffusion Magnetic Resonance Imaging - methods ; Glioblastoma - drug therapy ; Glioblastoma - pathology ; Glioblastoma - radiotherapy ; Glioblastoma multiforme ; Health aspects ; Humans ; Magnetic Resonance Imaging - methods ; Magnetic Resonance Spectroscopy - methods ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - pathology ; Nuclear magnetic resonance spectroscopy ; PET imaging ; Positron-Emission Tomography - methods ; Radiation Injuries - diagnosis ; Radiotherapy ; Randomized Controlled Trials as Topic ; Usage
ispartofNature reviews. Clinical oncology, 2009-11, Vol.6 (11), p.648-657
rights
0COPYRIGHT 2009 Nature Publishing Group
1Copyright Nature Publishing Group Nov 2009
lds50peer_reviewed
citedbyFETCH-LOGICAL-c451t-a19008db45440ed2efbaa7aabe1d4dac54a1614ce22e4056f5f7da5be02a0b113
citesFETCH-LOGICAL-c451t-a19008db45440ed2efbaa7aabe1d4dac54a1614ce22e4056f5f7da5be02a0b113
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19806145$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Aghi, Manish K
1Yang, Isaac
title
0New advances that enable identification of glioblastoma recurrence
1Nature reviews. Clinical oncology
addtitleNat Rev Clin Oncol
descriptionPostoperative adjuvant radiation therapy and temozolomide chemotherapy have become the standard care for newly diagnosed malignant gliomas. The efficacy of these therapies has led to an increase in pseudoprogression and radiation necrosis, both of which are treatment-related effects whose appearance on standard MRI with gadolinium-based contrast agents resembles that of tumor progression or recurrence. Accurate diagnosis of these post-treatment lesions as either tumor recurrence or treatment effects (pseudoprogression or radiation necrosis) is important to determine the patient's prognosis. Modern advancements with magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and PET scans have shown promise for distinguishing tumor recurrence from treatment effects. Advances in radiographic techniques will become critically important with the emergence of new antiangiogenic therapies. Consequently, MRS, DWI, and PET need to be incorporated into routine post-treatment investigations to improve the specificity and sensitivity of distinguishing tumor recurrence from treatment effects. Further research will also be needed to develop improved algorithms that use these modalities, and to develop new modalities with even greater accuracy than those currently available.
subject
0Antineoplastic Agents, Alkylating - therapeutic use
1Care and treatment
2Dacarbazine - analogs & derivatives
3Dacarbazine - therapeutic use
4Development and progression
5Diagnosis
6Diffusion Magnetic Resonance Imaging - methods
7Glioblastoma - drug therapy
8Glioblastoma - pathology
9Glioblastoma - radiotherapy
10Glioblastoma multiforme
11Health aspects
12Humans
13Magnetic Resonance Imaging - methods
14Magnetic Resonance Spectroscopy - methods
15Neoplasm Recurrence, Local - diagnosis
16Neoplasm Recurrence, Local - pathology
17Nuclear magnetic resonance spectroscopy
18PET imaging
19Positron-Emission Tomography - methods
20Radiation Injuries - diagnosis
21Radiotherapy
22Randomized Controlled Trials as Topic
23Usage
issn
01759-4774
11759-4782
fulltexttrue
rsrctypearticle
creationdate2009
recordtypearticle
recordideNp9kU1vVCEYhYnR2Fr9Ay7MTUyMm5kCF-7HsjZ-JY3d6Jq8F146NFyowLXpv5dxJlNrGsMCQp5z3gOHkNeMrhlth9OQtHchBr3mlI5rJukTcsx6Oa5EP_Cnh3MvjsiLnK8p7TrRt8_JERsH2jEhj8mHb3jbgPkFQWNuygZKgwEmj40zGIqzTkNxMTTRNlfexclDLnGGJqFeUsIqe0meWfAZX-33E_Lj08fv519WF5efv56fXay0kKysgI2UDmYSUgiKhqOdAHqACZkRBrQUwGomjZyjoLKz0vYG5ISUA50Ya0_I253vTYo_F8xFXcclhTpSMcrHoRf9KO6pK_CoXLCxJNCzy1qd8erSdW0rK7V-hKrL4Ox0DGhdvX8gePeXYIPgyyZHv2z_Jj8E-Q7UKeac0Kqb5GZIdzWk2tamDrWpbW2q1lZFb_ZPW6YZzb1k31MFhn9ctSt_iqm5nf-_9_udNEBZEh68H0F_Azlwtag
startdate200911
enddate200911
creator
0Aghi, Manish K
1Yang, Isaac
generalNature Publishing Group
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
83V.
97RV
107T5
117TM
127TO
137X7
147XB
1588E
168FE
178FH
188FI
198FJ
208FK
21ABUWG
22AZQEC
23BBNVY
24BENPR
25BHPHI
26DWQXO
27FYUFA
28GHDGH
29GNUQQ
30H94
31HCIFZ
32K9.
33KB0
34LK8
35M0S
36M1P
37M7P
38NAPCQ
39PQEST
40PQQKQ
41PQUKI
42PRINS
sort
creationdate200911
titleNew advances that enable identification of glioblastoma recurrence
authorAghi, Manish K ; Yang, Isaac
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c451t-a19008db45440ed2efbaa7aabe1d4dac54a1614ce22e4056f5f7da5be02a0b113
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Antineoplastic Agents, Alkylating - therapeutic use
1Care and treatment
2Dacarbazine - analogs & derivatives
3Dacarbazine - therapeutic use
4Development and progression
5Diagnosis
6Diffusion Magnetic Resonance Imaging - methods
7Glioblastoma - drug therapy
8Glioblastoma - pathology
9Glioblastoma - radiotherapy
10Glioblastoma multiforme
11Health aspects
12Humans
13Magnetic Resonance Imaging - methods
14Magnetic Resonance Spectroscopy - methods
15Neoplasm Recurrence, Local - diagnosis
16Neoplasm Recurrence, Local - pathology
17Nuclear magnetic resonance spectroscopy
18PET imaging
19Positron-Emission Tomography - methods
20Radiation Injuries - diagnosis
21Radiotherapy
22Randomized Controlled Trials as Topic
23Usage
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Aghi, Manish K
1Yang, Isaac
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7ProQuest Central (Corporate)
8Nursing & Allied Health Database
9Immunology Abstracts
10Nucleic Acids Abstracts
11Oncogenes and Growth Factors Abstracts
12Health & Medical Collection
13ProQuest Central (purchase pre-March 2016)
14Medical Database (Alumni Edition)
15ProQuest SciTech Collection
16ProQuest Natural Science Collection
17Hospital Premium Collection
18Hospital Premium Collection (Alumni Edition)
19ProQuest Central (Alumni) (purchase pre-March 2016)
20ProQuest Central (Alumni Edition)
21ProQuest Central Essentials
22Biological Science Collection
23ProQuest Central
24Natural Science Collection
25ProQuest Central Korea
26Health Research Premium Collection
27Health Research Premium Collection (Alumni)
28ProQuest Central Student
29AIDS and Cancer Research Abstracts
30SciTech Premium Collection
31ProQuest Health & Medical Complete (Alumni)
32Nursing & Allied Health Database (Alumni Edition)
33ProQuest Biological Science Collection
34Health & Medical Collection (Alumni Edition)
35Medical Database
36Biological Science Database
37Nursing & Allied Health Premium
38ProQuest One Academic Eastern Edition
39ProQuest One Academic
40ProQuest One Academic UKI Edition
41ProQuest Central China
jtitleNature reviews. Clinical oncology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Aghi, Manish K
1Yang, Isaac
formatjournal
genrearticle
ristypeJOUR
atitleNew advances that enable identification of glioblastoma recurrence
jtitleNature reviews. Clinical oncology
addtitleNat Rev Clin Oncol
date2009-11
risdate2009
volume6
issue11
spage648
epage657
pages648-657
issn1759-4774
eissn1759-4782
codenAJHYE6
abstractPostoperative adjuvant radiation therapy and temozolomide chemotherapy have become the standard care for newly diagnosed malignant gliomas. The efficacy of these therapies has led to an increase in pseudoprogression and radiation necrosis, both of which are treatment-related effects whose appearance on standard MRI with gadolinium-based contrast agents resembles that of tumor progression or recurrence. Accurate diagnosis of these post-treatment lesions as either tumor recurrence or treatment effects (pseudoprogression or radiation necrosis) is important to determine the patient's prognosis. Modern advancements with magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and PET scans have shown promise for distinguishing tumor recurrence from treatment effects. Advances in radiographic techniques will become critically important with the emergence of new antiangiogenic therapies. Consequently, MRS, DWI, and PET need to be incorporated into routine post-treatment investigations to improve the specificity and sensitivity of distinguishing tumor recurrence from treatment effects. Further research will also be needed to develop improved algorithms that use these modalities, and to develop new modalities with even greater accuracy than those currently available.
copEngland
pubNature Publishing Group
pmid19806145
doi10.1038/nrclinonc.2009.150